Naftidrofuryl Zentiva (Naftidrofuryl Oxalate)

Naftidrofuryl Zentiva is indicated for conditions involving impaired peripheral blood flow.

• Intermittent claudication: improves walking distance by enhancing limb perfusion.
• Peripheral arterial disease: reduces ischemic symptoms and supports tissue oxygenation.
• Cerebrovascular insufficiency: may alleviate transient ischemic episodes by improving cerebral microcirculation.

• Naftidrofuryl Oxalate selectively blocks 5‑HT2 serotonergic receptors on vascular smooth muscle, preventing serotonin‑induced vasoconstriction. This antagonism leads to relaxation of peripheral arteries and arterioles, increasing blood flow to skeletal muscle and cerebral tissues. The resulting improvement in microcirculatory dynamics reduces ischemic pain and supports tissue oxygen delivery without significant effect on heart rate or cardiac output and does not markedly alter systemic blood pressure.

Naftidrofuryl Zentiva may be associated with several adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea: mild stomach upset that may resolve without treatment.
• Headache: transient pain often relieved with simple analgesics.
• Dizziness: sensation of light‑headedness, usually temporary.
• Abdominal discomfort: mild cramps or pain in the stomach area.
• Flushing: brief redness of the skin, especially on the face.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that can cause fainting.
• Allergic reactions: rash, itching, swelling, or anaphylaxis requiring immediate care.
• Elevated liver enzymes: signs of hepatic stress that need laboratory monitoring.
• Neutropenia: reduced white blood cell count increasing infection risk.

Before prescribing Naftidrofuryl Zentiva, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: assess kidney function and adjust therapy if necessary.
• Hepatic dysfunction: monitor liver enzymes during treatment.
• Concomitant antihypertensives: watch for additive blood‑pressure lowering effects.
• Elderly patients: start at the lowest effective dose and titrate cautiously.
• Pregnancy and lactation: use only if the potential benefit outweighs the risk.
• Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Naftidrofuryl Zentiva can interact with other medicines; awareness of major and moderate interactions helps avoid adverse outcomes.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): combined use may cause profound hypotension.
• Nitrates or other vasodilators: additive vasodilatory effect can lead to unsafe blood‑pressure drops.
• Strong CYP2D6 inhibitors: may increase Naftidrofuryl plasma concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: monitor blood pressure for excessive lowering.
• Diuretics: observe electrolyte balance and renal function.
• Anticoagulants: watch for increased bleeding tendency.
• Alcohol: may enhance dizziness and hypotensive effects.